Vaxcyte Inc
NASDAQ:PCVX

Watchlist Manager
Vaxcyte Inc Logo
Vaxcyte Inc
NASDAQ:PCVX
Watchlist
Price: 35.89 USD -3.52% Market Closed
Market Cap: 4.6B USD

EV/EBIT
Enterprise Value to EBIT

-7.3
Current
-11.6
Median
4.5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-7.3
=
Enterprise Value
4.6B USD
/
EBIT
-636m USD
EBIT Growth EV/EBIT to Growth
US
Vaxcyte Inc
NASDAQ:PCVX
Average EV/EBIT: 20
Negative Multiple: -7.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 977.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.5
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -549.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -324.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-6.2
2-Years Forward
EV/EBIT
-6.2
3-Years Forward
EV/EBIT
-6.3